Image pharmaphorum Editor Views & Analysis Why AI equity is the next step for transformational pharma AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approach Views & Analysis Transformational therapies demand a new mindset Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Views & Analysis Deep Dive: Research and Development Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population. Load more results
Views & Analysis Why AI equity is the next step for transformational pharma AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approach
Views & Analysis Transformational therapies demand a new mindset Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges.
Views & Analysis Deep Dive: Research and Development Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel.
Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.